中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2012年
6期
366-370
,共5页
姚晓香%王晋芬%王跃华%高宁
姚曉香%王晉芬%王躍華%高寧
요효향%왕진분%왕약화%고저
淋巴瘤,大细胞,弥漫型%免疫表型分型%预后
淋巴瘤,大細胞,瀰漫型%免疫錶型分型%預後
림파류,대세포,미만형%면역표형분형%예후
Lymphoma,large B-cell,diffuse%Immunophenotyping%Prognosis
目的 探讨microRNA-223( miR-223)表达与弥漫性大B细胞淋巴瘤(DLBCL)免疫亚型及预后的相关关系.方法 应用免疫组织化学EnVision法对山西省肿瘤医院病理科有详细随访资料的45例DLBCL进行CD20、CD3、CD10、bcl-6、MUM-1免疫标记,根据Hans分类方法将DLBCL分为生发中心B细胞型(GCB型)和非GCB型;应用安捷伦16.0高密度芯片对24例有详细随访资料的DLBCL患者的石蜡样本进行miRNA表达谱筛选;采用TaqMan real-time逆转录聚合酶链反应( real-time RT-PCR)检测miR-223的表达水平,14例淋巴结反应性增生样本作为对照.结果 45例DLBCL中,GCB型16例(35.6％),非GCB型29例(64.4％).miR-223在GCB型中的相对表达量为19.8,在非GCB型中的相对表达量为15.8,二者差异无统计学意义(P=0.236).与淋巴结反应性增生相比较,miR-223在DLBCL中表达上调,其表达量是淋巴结反性增生的17.2倍,差异有统计学意义(P=0.014).DLBCL中miR-223高表达组(＞中位数)总体生存率高于低表达组(＜中位数),差异有统计学意义(P=0.011).多因素Cox模型分析显示:45例DLBCL中,miR-223低表达组(RR =5.445,95％CI 1.555～ 19.068,P=0.008)、乳酸脱氢酶异常水平(RR =3.974,95％ CI1.191～13.266,P =0.025)、国际预后指数≥3分(RR =4.044,95％CI 1.233～13.264,P=0.021)均为各自独立的预后不良的因素.结论 DLBCL中miR-223的表达与免疫亚型无关,miR-223高表达组总体生存率明显高于低表达组,提示miR-223可能为评估预后的另一个新型分子标志物.
目的 探討microRNA-223( miR-223)錶達與瀰漫性大B細胞淋巴瘤(DLBCL)免疫亞型及預後的相關關繫.方法 應用免疫組織化學EnVision法對山西省腫瘤醫院病理科有詳細隨訪資料的45例DLBCL進行CD20、CD3、CD10、bcl-6、MUM-1免疫標記,根據Hans分類方法將DLBCL分為生髮中心B細胞型(GCB型)和非GCB型;應用安捷倫16.0高密度芯片對24例有詳細隨訪資料的DLBCL患者的石蠟樣本進行miRNA錶達譜篩選;採用TaqMan real-time逆轉錄聚閤酶鏈反應( real-time RT-PCR)檢測miR-223的錶達水平,14例淋巴結反應性增生樣本作為對照.結果 45例DLBCL中,GCB型16例(35.6％),非GCB型29例(64.4％).miR-223在GCB型中的相對錶達量為19.8,在非GCB型中的相對錶達量為15.8,二者差異無統計學意義(P=0.236).與淋巴結反應性增生相比較,miR-223在DLBCL中錶達上調,其錶達量是淋巴結反性增生的17.2倍,差異有統計學意義(P=0.014).DLBCL中miR-223高錶達組(＞中位數)總體生存率高于低錶達組(＜中位數),差異有統計學意義(P=0.011).多因素Cox模型分析顯示:45例DLBCL中,miR-223低錶達組(RR =5.445,95％CI 1.555～ 19.068,P=0.008)、乳痠脫氫酶異常水平(RR =3.974,95％ CI1.191～13.266,P =0.025)、國際預後指數≥3分(RR =4.044,95％CI 1.233～13.264,P=0.021)均為各自獨立的預後不良的因素.結論 DLBCL中miR-223的錶達與免疫亞型無關,miR-223高錶達組總體生存率明顯高于低錶達組,提示miR-223可能為評估預後的另一箇新型分子標誌物.
목적 탐토microRNA-223( miR-223)표체여미만성대B세포림파류(DLBCL)면역아형급예후적상관관계.방법 응용면역조직화학EnVision법대산서성종류의원병이과유상세수방자료적45례DLBCL진행CD20、CD3、CD10、bcl-6、MUM-1면역표기,근거Hans분류방법장DLBCL분위생발중심B세포형(GCB형)화비GCB형;응용안첩륜16.0고밀도심편대24례유상세수방자료적DLBCL환자적석사양본진행miRNA표체보사선;채용TaqMan real-time역전록취합매련반응( real-time RT-PCR)검측miR-223적표체수평,14례림파결반응성증생양본작위대조.결과 45례DLBCL중,GCB형16례(35.6％),비GCB형29례(64.4％).miR-223재GCB형중적상대표체량위19.8,재비GCB형중적상대표체량위15.8,이자차이무통계학의의(P=0.236).여림파결반응성증생상비교,miR-223재DLBCL중표체상조,기표체량시림파결반성증생적17.2배,차이유통계학의의(P=0.014).DLBCL중miR-223고표체조(＞중위수)총체생존솔고우저표체조(＜중위수),차이유통계학의의(P=0.011).다인소Cox모형분석현시:45례DLBCL중,miR-223저표체조(RR =5.445,95％CI 1.555～ 19.068,P=0.008)、유산탈경매이상수평(RR =3.974,95％ CI1.191～13.266,P =0.025)、국제예후지수≥3분(RR =4.044,95％CI 1.233～13.264,P=0.021)균위각자독립적예후불량적인소.결론 DLBCL중miR-223적표체여면역아형무관,miR-223고표체조총체생존솔명현고우저표체조,제시miR-223가능위평고예후적령일개신형분자표지물.
Objective To study the expression of miR-223 in diffuse large B cell lymphoma (DLBCL) with correlation of histoloigcal subtypes and clinical prognosis.Methods A total of 45 cases of DLBCL were investigated by immunohistochemistry ( EnVision method) for CD20,CD3,CD10,bcl-6 and MUM-1.The cases were classified into germinal center B cell-like (GCB) and non-germinal center B celllike (non-GCB) subtypes according to Hans'algorithm.Agilent Human miRNA MicrOarray 16.0 was used to detect the expression of micro-RNAs in paraffin-embedded tissue of 24 cases of DLBCL that had available clinical follow-up.The expression levels of miR-223 were examined by TaqMan real-time reverse transcription polymerase chain reaction ( real-time RT-PCR).Fourteen cases of reactive lymph node were selected as control.Results Among 45 cases of DLBCL,16 cases ( 35.6％ ) were GCB,and 29 cases(64.4％ ) were non-GCB subtypes.The expression levels of miR-223 measured by real-time RT-PCR were 19.8 and 15.8 in GCB and non-GCB subgroups,respectively (P =0.236).The expression of miR-223 was up-regulated in DLBCL with 17.2 folds of increase over that of the reactive lymph nodes ( P =0.014).The overexpression of miR-223 was significandy correlated with a longer overall survival ( P =0.011 ).Multivariate Cox proportional hazard regression analysis identified the following independent poor prognostic factors:low expression of miR-223 (RR =5.445,95％ CI,1.555-19.068,P =0.008 ),abnormal level of LDH (RR=3.974,95％ CI,1.191-13.266,P=0.025) and IPI≥3 (RR =4,044,95％ CI,1.233-13.264,P =0.021).Conclusious The expression of miR-223 has no relationship with the immunophenotypes of DLBCL.As a potential prognostic biomarker,overexpression of miR-223 correlates with a longer OS of patients with DI,BCL.
